Pragyi Shrestha1, Saritha Adepu1, Romain R Vivès2, Rana El Masri2, Astrid Klooster3, Fleur Kaptein1, Wendy Dam1, Stephan J L Bakker1, Harry van Goor4, Bart van de Sluis5, Jacob van den Born6. 1. Department of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. 2. University Grenoble Alpes, Centre National de la Recherche Scientifique (CNRS), Commissariat à l'Energie Atomique (CEA), Institute of Structural Biology, Grenoble, France. 3. Department of Pathology, Pathology Friesland, Leeuwarden, The Netherlands. 4. Department Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. 5. Department Pediatrics, Section of Molecular Genetics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. 6. Department of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands j.van.den.born@umcg.nl.
Abstract
BACKGROUND: Dyslipidemia is an important risk factor in CKD. The liver clears triglyceride-rich lipoproteins (TRL) via LDL receptor (LDLR), LDLR-related protein-1 (LRP-1), and heparan sulfate proteoglycans (HSPGs), mostly syndecan-1. HSPGs also facilitate LDLR degradation by proprotein convertase subtilisin/kexin type 9 (PCSK9). Progressive renal failure affects the structure and activity of hepatic lipoprotein receptors, PCSK9, and plasma cholesterol. METHODS: Uninephrectomy- and aging-induced CKD in normotensive Wistar rats and hypertensive Munich-Wistar-Frömter (MWF) rats. RESULTS: Compared with 22-week-old sex- and strain-matched rats, 48-week-old uninephrectomized Wistar-CKD and MWF-CKD rats showed proteinuria, increased plasma creatinine, and hypercholesterolemia (all P<0.05), which were most apparent in hypertensive MWF-CKD rats. Hepatic PCSK9 expression increased in both CKD groups (P<0.05), with unusual sinusoidal localization, which was not seen in 22-week-old rats. Heparan sulfate (HS) disaccharide analysis, staining with anti-HS mAbs, and mRNA expression of HS polymerase exostosin-1 (Ext-1), revealed elongated HS chains in both CKD groups. Solid-phase competition assays showed that the PCSK9 interaction with heparin-albumin (HS-proteoglycan analogue) was critically dependent on polysaccharide chain length. VLDL binding to HS from CKD livers was reduced (P<0.05). Proteinuria and plasma creatinine strongly associated with plasma cholesterol, PCSK9, and HS changes. CONCLUSIONS: Progressive CKD induces hepatic HS elongation, leading to increased interaction with PCSK9. This might reduce hepatic lipoprotein uptake and thereby induce dyslipidemia in CKD. Therefore, PCSK9/HS may be a novel target to control dyslipidemia.
BACKGROUND: Dyslipidemia is an important risk factor in CKD. The liver clears triglyceride-rich lipoproteins (TRL) via LDL receptor (LDLR), LDLR-related protein-1 (LRP-1), and heparan sulfate proteoglycans (HSPGs), mostly syndecan-1. HSPGs also facilitate LDLR degradation by proprotein convertase subtilisin/kexin type 9 (PCSK9). Progressive renal failure affects the structure and activity of hepatic lipoprotein receptors, PCSK9, and plasma cholesterol. METHODS: Uninephrectomy- and aging-induced CKD in normotensive Wistar rats and hypertensive Munich-Wistar-Frömter (MWF) rats. RESULTS: Compared with 22-week-old sex- and strain-matched rats, 48-week-old uninephrectomized Wistar-CKD and MWF-CKD rats showed proteinuria, increased plasma creatinine, and hypercholesterolemia (all P<0.05), which were most apparent in hypertensive MWF-CKD rats. Hepatic PCSK9 expression increased in both CKD groups (P<0.05), with unusual sinusoidal localization, which was not seen in 22-week-old rats. Heparan sulfate (HS) disaccharide analysis, staining with anti-HS mAbs, and mRNA expression of HS polymerase exostosin-1 (Ext-1), revealed elongated HS chains in both CKD groups. Solid-phase competition assays showed that the PCSK9 interaction with heparin-albumin (HS-proteoglycan analogue) was critically dependent on polysaccharide chain length. VLDL binding to HS from CKD livers was reduced (P<0.05). Proteinuria and plasma creatinine strongly associated with plasma cholesterol, PCSK9, and HS changes. CONCLUSIONS: Progressive CKD induces hepatic HS elongation, leading to increased interaction with PCSK9. This might reduce hepatic lipoprotein uptake and thereby induce dyslipidemia in CKD. Therefore, PCSK9/HS may be a novel target to control dyslipidemia.
Authors: Barbara E Stopschinski; Brandon B Holmes; Gregory M Miller; Victor A Manon; Jaime Vaquer-Alicea; William L Prueitt; Linda C Hsieh-Wilson; Marc I Diamond Journal: J Biol Chem Date: 2018-05-11 Impact factor: 5.157
Authors: Allan J Collins; Shuling Li; David T Gilbertson; Jiannong Liu; Shu-Cheng Chen; Charles A Herzog Journal: Kidney Int Suppl Date: 2003-11 Impact factor: 10.545
Authors: Kristin I Stanford; Joseph R Bishop; Erin M Foley; Jon C Gonzales; Ingrid R Niesman; Joseph L Witztum; Jeffrey D Esko Journal: J Clin Invest Date: 2009-10-01 Impact factor: 14.808
Authors: Christopher P Cannon; Bertrand Cariou; Dirk Blom; James M McKenney; Christelle Lorenzato; Robert Pordy; Umesh Chaudhari; Helen M Colhoun Journal: Eur Heart J Date: 2015-02-16 Impact factor: 29.983
Authors: Theodosios D Filippatos; Evangelos Liberopoulos; Maria Georgoula; Constantinos C Tellis; Alexandros D Tselepis; Moses Elisaf Journal: Arch Med Sci Atheroscler Dis Date: 2017-10-05
Authors: Pragyi Shrestha; Kirankumar Katta; Ditmer Talsma; Annamaria Naggi; Jan-Luuk Hillebrands; Bart van de Sluis; Jacob van den Born Journal: Front Cell Dev Biol Date: 2022-03-07